Colon Cancer Progression Is Reflected to Monotonic Differentiation in Gene Expression and Pathway Deregulation Facilitating Stage–specific Drug Repurposing
| Autor: | Marilena M. Bourdakou, George M. Spyrou, George Kolios |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
Colorectal cancer In silico Drug Repositioning Cancer Cell Differentiation Biology medicine.disease Colon cancer staging Biochemistry Gene Expression Regulation Neoplastic Transcriptome Drug repositioning Colonic Neoplasms Gene expression Disease Progression Genetics medicine Cancer research Humans Molecular Biology Gene Research Article |
| Zdroj: | Cancer Genomics Proteomics |
| ISSN: | 1790-6245 1109-6535 |
| DOI: | 10.21873/cgp.20295 |
| Popis: | Background/Aim: Colon cancer is one of the most common cancer types and the second leading cause of death due to cancer. Many efforts have been performed towards the investigation of molecular alterations during colon cancer progression. However, the identification of stage-specific molecular markers remains a challenge. The aim of this study was to develop a novel computational methodology for the analysis of alterations in differential gene expression and pathway deregulation across colon cancer stages in order to reveal stage-specific biomarkers and reinforce drug repurposing investigation. Materials and Methods: Transcriptomic datasets of colon cancer were used to identify (a) differentially expressed genes with monotonicity in their fold changes (MEGs) and (b) perturbed pathways with ascending monotonic enrichment (MEPs) related to the number of the participating differentially expressed genes (DEGs), across the four colon cancer stages. Through an in silico drug repurposing pipeline we identified drugs that regulate the expression of MEGs and also target the resulting MEPs. Results: Our methodology highlighted 15 MEGs and 32 candidate repurposed drugs that affect their expression. We also found 51 MEPs divided into two groups according to their rate of DEG content alteration across colon cancer stages. Focusing on the target MEPs of the highlighted repurposed drugs, we found that one of them, the neuroactive ligand-receptor interaction, was targeted by the majority of the candidate drugs. Moreover, we observed that two of the drugs (PIK-75 and troglitazone) target the majority of the resulting MEPs. Conclusion: These findings highlight significant genes and pathways that can be used as stage-specific biomarkers and facilitate the discovery of new potential repurposed drugs for colon cancer. We expect that the computational methodology presented can be applied in a similar way to the analysis of any progressive disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|